Low LATS2 EXPRESSION IS ASSOCIATED WITH POOR PROGNOSIS IN NON-SMALL CELL LUNG CARCINOMA
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jang, Si-Hyong | - |
dc.contributor.author | Oh, Mee-Hye | - |
dc.contributor.author | Cho, Hyun Deuk | - |
dc.contributor.author | Lee, Ji-Hye | - |
dc.contributor.author | Lee, Hyun Ju | - |
dc.contributor.author | Ahn, Hyein | - |
dc.contributor.author | Kim, Han Jo | - |
dc.date.accessioned | 2021-08-11T11:23:35Z | - |
dc.date.available | 2021-08-11T11:23:35Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1233-9687 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/5306 | - |
dc.description.abstract | Large tumor suppressor kinase 2 (LATS2) is a core component in the Hippo signaling pathway, and it functions as a tumor suppressor associated with tumor cell proliferation and apoptosis. The purpose of this study is to explore LATS2 expression and its clinicopathological significance in non-small cell lung cancer (NSCLC). We examined LATS2 protein expression by immunohistochemistry in 184 resected NSCLC specimens using tissue microarrays. Low LATS2 expression was significantly related to disease recurrence (p = 0.047). In survival analysis, the low LATS2 expression group showed a statistically poorer overall survival (OS) (p = 0.004) and disease-free survival (DFS) (p = 0.014) than the high expression group. In multivariate analysis, downregulated LATS2 expression in NSCLC could be an independent prognostic factor of poor OS and DFS. Furthermore, we evaluated the prognostic significance of LATS2 expression in two major NSCLC subtypes, squamous cell carcinoma and adenocarcinoma. The low LATS2 expression group showed worse prognosis than the high LATS2 expression group (OS [p = 0.144] and DFS [p = 0.022] in squamous cell carcinoma and OS [p = 0.045) and DFS [p = 0.271] in adenocarcinoma). We demonstrated that downregulated LATS2 expression may predict aggressive biologic behavior and a worse prognosis in NSCLC and we also suggested the possibility of LATS2 as a therapeutic target in both squamous cell carcinoma and adenocarcinoma. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Polskie Towarzystwo Patologow/Polish Society of Pathologists | - |
dc.title | Low LATS2 EXPRESSION IS ASSOCIATED WITH POOR PROGNOSIS IN NON-SMALL CELL LUNG CARCINOMA | - |
dc.type | Article | - |
dc.publisher.location | 폴란드 | - |
dc.identifier.doi | 10.5114/PJP.2019.90395 | - |
dc.identifier.scopusid | 2-s2.0-85076303360 | - |
dc.identifier.wosid | 000501480800005 | - |
dc.identifier.bibliographicCitation | Polish Journal of Pathology, v.70, no.3, pp 189 - 197 | - |
dc.citation.title | Polish Journal of Pathology | - |
dc.citation.volume | 70 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 189 | - |
dc.citation.endPage | 197 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pathology | - |
dc.relation.journalWebOfScienceCategory | Pathology | - |
dc.subject.keywordPlus | PUTATIVE TUMOR-SUPPRESSOR | - |
dc.subject.keywordPlus | DOWN-REGULATION | - |
dc.subject.keywordPlus | PROMOTER HYPERMETHYLATION | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | RECURRENCE | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | HIPPO | - |
dc.subject.keywordAuthor | LATS2 | - |
dc.subject.keywordAuthor | Hippo pathway | - |
dc.subject.keywordAuthor | non-small cell lung cancer | - |
dc.subject.keywordAuthor | immunohistochemistry | - |
dc.subject.keywordAuthor | prognosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.